NCT03507205: Grand-DES

Korean Nationwide Multicenter Pooled Registry of Drug-Eluting Stents

Completed Last updated 24 April 2018

What this trial tests

trial testing Biomatrix; Biomatrix Flex; Nobori in Coronary Artery Disease in 17,286 participants. Completed in 30 November 2017.

Timeline

1 April 2008

Primary endpoint
1 November 2017

30 November 2017

Quick facts

Lead sponsor	Seoul National University Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	17,286
Start date	1 April 2008
Primary completion	1 November 2017
Estimated completion	30 November 2017
Sites	37 locations across South Korea

Drugs / interventions tested

• Biomatrix; Biomatrix Flex; Nobori
• Xience Prime
• Xience V/Promus; Cypher
• DP-ZES-RI
• Endeavor; Resolute

Conditions studied

• Coronary Artery Disease — all drugs for Coronary Artery Disease →

Sponsor

Seoul National University Hospital

Who can join

Eligibility, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the long-term efficacy and safety of coronary stenting with the various types of drug-eluting stents (DES) and to determine clinical device and procedural success during commercial use of DES in the real world.

The investigators will compare EES (Xience V/Promus and Xience Prime), SES (Cypher), ZES (Resolute Integrity, Endeavor Resolute, Endeavor), and BES (Biomatrix, Biomatrix Flex, and Nobori).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Sarcopenia Index as a Predictor of Clinical Outcomes in Older Patients with Coronary Artery Disease.
   Lee HS, Park KW, Kang J, Ki YJ, et al · · 2020 · cited 33× · PMID 32992530 · DOI 10.3390/jcm9103121
2. Relative Impact of Clinical Risk Versus Procedural Risk on Clinical Outcomes After Percutaneous Coronary Intervention.
   Kang J, Park KW, Lee HS, Zheng C, et al · · 2021 · cited 25× · PMID 33541106 · DOI 10.1161/circinterventions.120.009642
3. Complete Revascularization of Multivessel Coronary Artery Disease Does Not Improve Clinical Outcome in ST-Segment Elevation Myocardial Infarction Patients with Reduced Left Ventricular Ejection Fraction.
   Kang J, Zheng C, Park KW, Park J, et al · · 2020 · cited 6× · PMID 31952345 · DOI 10.3390/jcm9010232
4. Angiographic complete revascularization versus incomplete revascularization in patients with diabetes mellitus.
   Hwang D, Park J, Yang HM, Yang S, et al · · 2022 · cited 5× · PMID 35439958 · DOI 10.1186/s12933-022-01488-7
5. Impact of Intensive Glucose Control in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: 3-Year Clinical Outcomes.
   Park J, Han JK, Chang M, Ki YJ, et al · · 2020 · cited 4× · PMID 32752146 · DOI 10.3390/jcm9082464
6. Impact of Complete Revascularization for Acute Myocardial Infarction In Multivessel Coronary Artery Disease Patients With Diabetes Mellitus.
   Kang J, Park S, Han M, Park KW, et al · · 2024 · cited 3× · PMID 38956939 · DOI 10.4070/kcj.2024.0017
7. The Clinical Impact of β-Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention.
   Park J, Han JK, Kang J, Chae IH, et al · · 2022 · cited 3× · PMID 35491482 · DOI 10.4070/kcj.2021.0395
8. Safety and Efficacy of Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Myocardial Infarction in the Presence of Intracoronary Thrombus: An Analysis From the Grand Drug-eluting Stent Registry.
   Zheng C, Kang J, Yang HM, Han JK, et al · · 2020 · cited 3× · PMID 32224030 · DOI 10.1016/j.clinthera.2020.02.022